Alnylam Pharmaceuticals, Inc. (ALNY) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $147.18 +0.95%
Revenue Growth %: +33.0%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: +33.0%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q1 EPS of ($0.25), $0.11 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $19.57 million.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- Invesco (IVZ) PT Lowered to $17 at BMO Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
